Curie Capital
Overview
Curie Capital is a life sciences focused venture capital firm that specializes in investing in early-stage companies in the biotechnology, pharmaceutical, and medical technology sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Avidicure | Apr 2025 | Seed | Co-investor |
| Flindr Therapeutics | Apr 2024 | Series A | Co-investor |
| Sirius Medical | Feb 2025 | Series B | Co-investor |
| Laigo Bio | Mar 2026 | Seed | Co-investor |
| Citryll | Dec 2024 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Curie Capital based?
Curie Capital is headquartered in Amsterdam, Netherlands.
When was Curie Capital founded?
Curie Capital was founded in 2018.
How many portfolio companies does Curie Capital have?
Curie Capital has 8 portfolio companies in Caplight's dataset.
What are some companies in Curie Capital's portfolio?
Portfolio companies visible on Caplight include Avidicure, Flindr Therapeutics, Sirius Medical, Laigo Bio, Citryll.
What was Curie Capital's most recent investment shown here?
Curie Capital's most recent investment in this portfolio sample was in Laigo Bio in 2026.
What sectors does Curie Capital focus on?
Curie Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Curie Capital focus on?
Curie Capital typically invests at the Early stage.
What is Curie Capital's AUM?
Curie Capital's assets under management are estimated between $22.5M and $22.5M.